Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics announced the initiation of the Phase 3 EMERGE trial evaluating Claseprubart in patients with acetylcholine receptor antibody positive generalized Myasthenia Gravis. The global study will enroll approximately 195 participants to assess subcutaneous dosing every two or four weeks, with top-line results anticipated in the second half of 2028.
Key figures
- Drug Name
- Claseprubart
- Phase Of Trial
- Phase 3
- Topline date
- 2H'28
- Dosing regimen
- 300mg/2mL S.C. Q2W and Q4W
- Participant count
- 195
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.